Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 tra...

Full description

Bibliographic Details
Main Authors: Ales Sorf, Simona Sucha, Anselm Morell, Eva Novotna, Frantisek Staud, Alzbeta Zavrelova, Benjamin Visek, Vladimir Wsol, Martina Ceckova
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
acute myeloid leukemia
CDK4/6 inhibitors
ABC transporters
drug resistance
Online Access:https://www.mdpi.com/2072-6694/12/6/1596

Internet

https://www.mdpi.com/2072-6694/12/6/1596

Similar Items